(VIANEWS) – The NASDAQ opens in less than one hour and ImmunoGen‘s pre-market value is already 4.72% down.
ImmunoGen’s last close was $5.30, 31.79% below its 52-week high of $7.77.
The last session, NASDAQ finished with ImmunoGen (IMGN) sliding 2.39% to $5.30. NASDAQ dropped 2% to $11,014.89, after three sequential sessions in a row of losses, on what was an all-around negative trend trading session.
ImmunoGen, Inc., is a biotechnology company in clinical stage. It develops ADC therapies for cancer. Mirvetuximab Soravtansine is an ADC which targets folate receptor alpha (FRa) and is currently in Phase III clinical trials. Pivekimab Sunirine is a CD123-targeting ADC and is currently in Phase II clinical trials to treat acute myeloid and blastic plasmacytoid cell neplasma. Preclinical programs for the company include IMGC936, which is an ADC co-developed with MacroGenics, Inc., and IMGN151, which are anti-FRa product candidates. Collaborations include Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CymX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. ImmunoGen, Inc., was established in 1980 and has its headquarters in Waltham, Massachusetts.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.25.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -100.96%.
The current reported ImmunoGen volume is 1741918, which is 67.2% lower than its average volume of 367440.
More news about ImmunoGen (IMGN).